Bartholomew Dzudzor, Samuel Essel, Latif Musah, Jennifer Adjepong Agyekum, Kwame Yeboah
{"title":"加纳城郊医院HIV患者代谢综合征和联合抗逆转录病毒治疗:一项病例对照研究","authors":"Bartholomew Dzudzor, Samuel Essel, Latif Musah, Jennifer Adjepong Agyekum, Kwame Yeboah","doi":"10.1155/2023/1566001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is an increasing prevalence of cardiovascular diseases (CVDs) and risk factors in HIV patients as the levels of AIDS-related mortality and morbidity decrease. Metabolic syndrome (MetS) is the accumulation of various CVD risk factors that predict the occurrence of CVDs. We investigated the prevalence of MetS and associated risk factors in HIV patients treated with combination antiretroviral therapy (cART), cART-naïve HIV patients, and non-HIV controls.</p><p><strong>Methods: </strong>In a case-control design, 158 cART-treated HIV patients, 150 cART-naïve HIV patients, and 156 non-HIV controls were recruited from a periurban hospital in Ghana. A structured questionnaire was used to collect data on demography, lifestyle, and medication. Anthropometric indices and blood pressure were measured. Fasting blood samples were collected to measure the plasma levels of glucose, lipid profile, and CD4+ cells. The presence of MetS was defined using the joint scientific statement criteria.</p><p><strong>Results: </strong>The prevalence of MetS was higher in cART-treated HIV patients compared with cART-naïve HIV patients and non-HIV controls (57.3% vs. 23.6% vs. 19.2% and <i>p</i> < 0.001, respectively). MetS was associated with cART-treated HIV patients (odds ratio (95% CI) = 7.24 (3.41-15.39) and <i>p</i> < 0.001), cART-naïve HIV patients (2.04 (1.01-4.15), <i>p</i>=0.048), and female gender (2.42 (1.39-4.23) and <i>p</i>=0.002). In cART-treated HIV patients, those on zidovudine (AZT)-based regimens were associated with increased likelihood (3.95 (1.49-10.43) and <i>p</i> < 0.006), while those on tenofovir (TDF)-based had decreased likelihood (0.32 (0.13-0.8) and <i>p</i>=0.015) of having MetS.</p><p><strong>Conclusion: </strong>In our study population, there was a high prevalence of MetS in cART-treated HIV patients compared to cART-naïve HIV patients and non-HIV controls. HIV patients on AZT-based regimens had an increased likelihood of having MetS, while those on TDF-based regimens had a reduced likelihood of having MetS.</p>","PeriodicalId":46303,"journal":{"name":"AIDS Research and Treatment","volume":"2023 ","pages":"1566001"},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957619/pdf/","citationCount":"4","resultStr":"{\"title\":\"Metabolic Syndrome and Combination Antiretroviral Therapy in HIV Patients in Periurban Hospital in Ghana: A Case-Control Study.\",\"authors\":\"Bartholomew Dzudzor, Samuel Essel, Latif Musah, Jennifer Adjepong Agyekum, Kwame Yeboah\",\"doi\":\"10.1155/2023/1566001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is an increasing prevalence of cardiovascular diseases (CVDs) and risk factors in HIV patients as the levels of AIDS-related mortality and morbidity decrease. Metabolic syndrome (MetS) is the accumulation of various CVD risk factors that predict the occurrence of CVDs. We investigated the prevalence of MetS and associated risk factors in HIV patients treated with combination antiretroviral therapy (cART), cART-naïve HIV patients, and non-HIV controls.</p><p><strong>Methods: </strong>In a case-control design, 158 cART-treated HIV patients, 150 cART-naïve HIV patients, and 156 non-HIV controls were recruited from a periurban hospital in Ghana. A structured questionnaire was used to collect data on demography, lifestyle, and medication. Anthropometric indices and blood pressure were measured. Fasting blood samples were collected to measure the plasma levels of glucose, lipid profile, and CD4+ cells. The presence of MetS was defined using the joint scientific statement criteria.</p><p><strong>Results: </strong>The prevalence of MetS was higher in cART-treated HIV patients compared with cART-naïve HIV patients and non-HIV controls (57.3% vs. 23.6% vs. 19.2% and <i>p</i> < 0.001, respectively). MetS was associated with cART-treated HIV patients (odds ratio (95% CI) = 7.24 (3.41-15.39) and <i>p</i> < 0.001), cART-naïve HIV patients (2.04 (1.01-4.15), <i>p</i>=0.048), and female gender (2.42 (1.39-4.23) and <i>p</i>=0.002). In cART-treated HIV patients, those on zidovudine (AZT)-based regimens were associated with increased likelihood (3.95 (1.49-10.43) and <i>p</i> < 0.006), while those on tenofovir (TDF)-based had decreased likelihood (0.32 (0.13-0.8) and <i>p</i>=0.015) of having MetS.</p><p><strong>Conclusion: </strong>In our study population, there was a high prevalence of MetS in cART-treated HIV patients compared to cART-naïve HIV patients and non-HIV controls. HIV patients on AZT-based regimens had an increased likelihood of having MetS, while those on TDF-based regimens had a reduced likelihood of having MetS.</p>\",\"PeriodicalId\":46303,\"journal\":{\"name\":\"AIDS Research and Treatment\",\"volume\":\"2023 \",\"pages\":\"1566001\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957619/pdf/\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/1566001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/1566001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 4
摘要
背景:随着艾滋病相关死亡率和发病率水平的降低，HIV患者中心血管疾病(cvd)和危险因素的患病率呈上升趋势。代谢综合征(MetS)是各种心血管疾病危险因素的积累，可以预测心血管疾病的发生。我们调查了接受联合抗逆转录病毒治疗(cART)的HIV患者、cART-naïve HIV患者和非HIV对照组中met的患病率和相关危险因素。方法:在病例对照设计中，从加纳的一家城市周边医院招募了158名cart治疗的HIV患者，150名cART-naïve HIV患者和156名非HIV对照组。采用结构化问卷收集人口统计、生活方式和药物方面的数据。测量人体测量指标和血压。收集空腹血液样本，测量血糖、血脂和CD4+细胞的血浆水平。使用联合科学声明标准来定义MetS的存在。结果:与cART-naïve HIV患者和非HIV对照组相比，cart治疗的HIV患者的MetS患病率更高(57.3% vs. 23.6% vs. 19.2%， p < 0.001)。met与cart治疗的HIV患者(优势比(95% CI) = 7.24 (3.41-15.39)， p < 0.001)、cART-naïve HIV患者(2.04 (1.01-4.15)，p=0.048)和女性(2.42 (1.39-4.23)，p=0.002)相关。在cart治疗的HIV患者中，以齐多夫定(AZT)为基础的方案与发生MetS的可能性增加相关(3.95 (1.49-10.43)，p < 0.006)，而以替诺福韦(TDF)为基础的方案与发生MetS的可能性降低相关(0.32 (0.13-0.8)，p=0.015)。结论:在我们的研究人群中，与cART-naïve HIV患者和非HIV对照组相比，cart治疗的HIV患者中MetS的患病率较高。以azt为基础的治疗方案的HIV患者发生MetS的可能性增加，而以tdf为基础的治疗方案的患者发生MetS的可能性降低。
Metabolic Syndrome and Combination Antiretroviral Therapy in HIV Patients in Periurban Hospital in Ghana: A Case-Control Study.
Background: There is an increasing prevalence of cardiovascular diseases (CVDs) and risk factors in HIV patients as the levels of AIDS-related mortality and morbidity decrease. Metabolic syndrome (MetS) is the accumulation of various CVD risk factors that predict the occurrence of CVDs. We investigated the prevalence of MetS and associated risk factors in HIV patients treated with combination antiretroviral therapy (cART), cART-naïve HIV patients, and non-HIV controls.
Methods: In a case-control design, 158 cART-treated HIV patients, 150 cART-naïve HIV patients, and 156 non-HIV controls were recruited from a periurban hospital in Ghana. A structured questionnaire was used to collect data on demography, lifestyle, and medication. Anthropometric indices and blood pressure were measured. Fasting blood samples were collected to measure the plasma levels of glucose, lipid profile, and CD4+ cells. The presence of MetS was defined using the joint scientific statement criteria.
Results: The prevalence of MetS was higher in cART-treated HIV patients compared with cART-naïve HIV patients and non-HIV controls (57.3% vs. 23.6% vs. 19.2% and p < 0.001, respectively). MetS was associated with cART-treated HIV patients (odds ratio (95% CI) = 7.24 (3.41-15.39) and p < 0.001), cART-naïve HIV patients (2.04 (1.01-4.15), p=0.048), and female gender (2.42 (1.39-4.23) and p=0.002). In cART-treated HIV patients, those on zidovudine (AZT)-based regimens were associated with increased likelihood (3.95 (1.49-10.43) and p < 0.006), while those on tenofovir (TDF)-based had decreased likelihood (0.32 (0.13-0.8) and p=0.015) of having MetS.
Conclusion: In our study population, there was a high prevalence of MetS in cART-treated HIV patients compared to cART-naïve HIV patients and non-HIV controls. HIV patients on AZT-based regimens had an increased likelihood of having MetS, while those on TDF-based regimens had a reduced likelihood of having MetS.
期刊介绍：
AIDS Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis of disease to translational and clinical research. In addition, articles relating to prevention, education, and behavior change will be considered
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
